Clinical Trial Detail

NCT ID NCT02984683
Title Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sanofi
Indications

triple-receptor negative breast cancer

Therapies

SAR566658

Age Groups: adult senior

No variant requirements are available.